EWEdwards Lifesciences
About Edwards Lifesciences
Edwards Lifesciences (NYSE:EW) specializes in the development and marketing of products and technologies for critical care, vascular therapy, and surgical monitoring. The company is primarily focused on innovations in heart valves and hemodynamic monitoring. Its projects range from transcatheter heart valve therapies to surgical heart valve solutions, aiming to address a variety of cardiovascular issues. Edwards Lifesciences' objectives include improving patient outcomes and enhancing the quality of life for people with cardiovascular disease through a commitment to innovation and excellence in their field. With a global presence, Edwards Lifesciences is dedicated to advancing the treatment of structural heart disease and critically ill patients around the world.
What is EW known for?
Snapshot
Public US
Ownership
1958
Year founded
12960
Employees
Irvine, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Irvine, US
Produtos e/ou serviços de Edwards Lifesciences
- Transcatheter aortic valve replacement (TAVR) systems designed for minimally invasive heart valve replacement in patients with severe aortic stenosis.
- Surgical heart valves for open-heart surgery, offering durable solutions for valve replacement.
- Critical care monitoring products that measure hemodynamic parameters to aid in managing critically ill patients.
- Transcatheter mitral and tricuspid therapies targeting mitral regurgitation and tricuspid regurgitation with minimally invasive procedures.
- Heart valve repair products, including annuloplasty rings to reconstruct heart valves.
- Portable blood analysis systems providing real-time, lab-quality diagnostic results for acute care settings.
equipe executiva do Edwards Lifesciences
- Mr. Bernard J. ZovighianCEO & Director
- Mr. Scott B. UllemCorporate VP & CFO
- Mr. Donald E. Bobo Jr.Corporate Vice President of Strategy & Corporate Development
- Mr. Jean-Luc LemercierCorporate Vice President of Japan, Asia Pacific & Greater China
- Mr. Daveen ChopraCorporate Vice President of Transcatheter Mitral & Tricuspid Therapies
- Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller
- Dr. Todd J. Brinton FACC, M.D.Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
- Mr. Snehashish SarkarSenior VP, Chief Information & Digital Officer
- Mr. Mark D. PetersonCorporate VP & General Counsel
- Mr. Dirksen J. LehmanCorporate Vice President of Public Affairs